Press release

Press Release

July 2022

Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries

Link

July 2022
May 2022

SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems

Link

May 2022
Apr 2022

Medigus: Polyrizon’s PL-15 Found Effective Against Highly Transmissible SARS-CoV-2 Omicron Variant in Cell Culture Assays

Link

Apr 2022
Mar 2022

Medigus: Prof. Nancy Agmon-Levin Joins Polyrizon’s Scientific Advisory Board

Link

Mar 2022
Dec 2021

Polyrizon to Test its Product Candidate for Protection Against the Highly Transmissible Corona Virus Omicron Variant

Link
Dec 2021
Nov 2021

Polyrizon Innovative Technology Demonstrated it may Prevent Allergic Reaction Caused by Common Allergens in a Cell-Culture Assay

Link

Nov 2021
Oct 2021

Polyrizon to Initiate Processes Towards FDA Submission

Link

Oct 2021
Sep 2021

Polyrizon to Test its Product Candidate for Protection Against High Transmissible Corona Virus Delta Variant B.1.617.2

Link

Sep 2021
Sep 2021

Polyrizon Submits a Patent Application for Prevention of Pathogens such as Coronavirus and Allergens from Affecting Nasal Tissue

Link

Sep 2021
Aug 2021

Polyrizon’s Innovative Technology Found Effective Against Influenza Virus H1N1 in Cell Culture Assays

Link

Aug 2021
Jul 2021

Polyrizon’s Innovative Proprietary Technology Found Effective Against Coronavirus in a Cell-Culture Assay

Link

Jul 2021
Nov 2020

Medigus to Invest up to an Additional $150,000 in COVID-19 Protection Biogel Developer Polyrizon

Link

Nov 2020
Jul 2020

Medigus inks license deal with Polyrizon

Link

Jul 2020
May 2020

Polyrizon Filed a US Patent Application for Formulations and Methods forPreventing Viral Infections by COVID-19 Virus

Link

May 2020
Apr 2020

MEDIGUS signed a binding letter of intent with POLYRIZON

Link

Apr 2020